These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 36358724)

  • 1. The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer.
    Khaddour K; Felipe Fernandez M; Khabibov M; Garifullin A; Dressler D; Topchu I; Patel JD; Weinberg F; Boumber Y
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.
    Catalano F; Borea R; Puglisi S; Boutros A; Gandini A; Cremante M; Martelli V; Sciallero S; Puccini A
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA Damage Response Deficiency in Thoracic Cancers.
    Bzura A; Spicer JB; Dulloo S; Yap TA; Fennell DA
    Drugs; 2024 Sep; 84(9):1025-1033. PubMed ID: 39001941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    Min A; Lee KH; Im SA
    Adv Exp Med Biol; 2021; 1187():159-179. PubMed ID: 33983578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer.
    Dai J; Jiang M; He K; Wang H; Chen P; Guo H; Zhao W; Lu H; He Y; Zhou C
    Front Oncol; 2021; 11():708294. PubMed ID: 34604048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
    Mao X; Lee NK; Saad SE; Fong IL
    Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy.
    Ali RMM; McIntosh SA; Savage KI
    Genes Chromosomes Cancer; 2021 May; 60(5):358-372. PubMed ID: 33247475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    Mekonnen N; Yang H; Shin YK
    Front Oncol; 2022; 12():880643. PubMed ID: 35785170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA damage response as a therapeutic target in gynecological cancers.
    Leary A; Auguste A; Mesnage S
    Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of DNA damage repair in cancer: from mechanisms to applications.
    Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
    Ann Transl Med; 2020 Dec; 8(24):1685. PubMed ID: 33490197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside.
    Boussios S; Rassy E; Moschetta M; Ghose A; Adeleke S; Sanchez E; Sheriff M; Chargari C; Pavlidis N
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
    Huang JL; Chang YT; Hong ZY; Lin CS
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients.
    Dalmasso B; Puccini A; Catalano F; Borea R; Iaia ML; Bruno W; Fornarini G; Sciallero S; Rebuzzi SE; Ghiorzo P
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
    van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
    Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of DNA damage repair alterations on prostate cancer progression and metastasis.
    Lukashchuk N; Barnicle A; Adelman CA; Armenia J; Kang J; Barrett JC; Harrington EA
    Front Oncol; 2023; 13():1162644. PubMed ID: 37434977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.